NCT04282954View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

October 20, 2020

Study Completion Date

December 11, 2020

Conditions
GERD
Interventions
DRUG

JP-1366

JP-1366, QD

DRUG

JP-1366 placebo

JP-1366 placebo, QD

DRUG

Esomeprazole 40mg

Esomeprazole 40mg, QD

DRUG

Esomeprazole placebo

Esomeprazole placebo, QD

Trial Locations (1)

Unknown

Severance Hospital and 19 hospitals, Seoul

Sponsors
All Listed Sponsors
lead

Onconic Therapeutics Inc.

INDUSTRY

NCT04282954 - Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter